XHELHRTIS
Market cap32mUSD
Dec 23, Last price
1.56EUR
1D
-5.45%
1Q
6.85%
Jan 2017
-45.26%
IPO
-85.11%
Name
Herantis Pharma Oyj
Chart & Performance
P/E
112.39
P/S
—
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
27.16%
Rev. gr., 5y
%
Revenues
0k
Net income
280k
CFO
-5m
L-99.48%
Earnings
Apr 24, 2025
Profile
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 2,700 | 5,000 | 6,200 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (2,700) | (5,000) | (6,200) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (1) | 1,332 | 308 | |||||||
Tax Rate | ||||||||||
NOPAT | (2,700) | (6,332) | (6,508) | |||||||
Net income | 280 | |||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,507 | 870,964 | 4,040 | |||||||
BB yield | -16.59% | -3,602.10% | -15.68% | |||||||
| Debt | ||||||||||
Debt current | 15,021 | 912 | ||||||||
Long-term debt | 72 | 439,089 | 6,421 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (14) | 1 | ||||||||
Net debt | (6,416) | (144,974) | (92) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (4,636) | (894,391) | ||||||||
CAPEX | ||||||||||
Cash from investing activities | 607 | (21,013) | (1,054) | |||||||
Cash from financing activities | 4,496 | 855,942 | 4,034 | |||||||
FCF | (2,700) | (6,332) | (6,508) | |||||||
| Balance | ||||||||||
Cash | 6,488 | 599,084 | 7,425 | |||||||
Long term investments | ||||||||||
Excess cash | 6,488 | 599,084 | 7,425 | |||||||
Stockholders' equity | 4,726 | (7,454,730) | 66,610 | |||||||
Invested Capital | 77 | 7,902,812 | (1,365) | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 17,195 | 14,654 | 10,731 | |||||||
Price | 1.58 -4.24% | 1.65 -31.25% | 2.40 -42.17% | |||||||
Market cap | 27,168 12.36% | 24,179 -6.12% | 25,754 -20.18% | |||||||
EV | 20,752 | (120,795) | 25,663 | |||||||
EBITDA | (2,700) | 10,971 | (3,480) | |||||||
EV/EBITDA | ||||||||||
Interest | 552 | 1,332 | 308 | |||||||
Interest/NOPBT | ||||||||||